---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-016535"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-05-13T12:00:58+00:00"
generated_at: "2026-05-13T12:08:25.148784+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Moleculin reports preliminary blinded CR rate ~30% in MIRACLE trial; first unblinding before June 30

## Summary
- Preliminary blinded CRc >40%, CR ~30% vs. historical ~17-18% for cytarabine alone.
- First unblinding of 45-subject data expected before June 30, 2026; ~30 Annamycin + cytarabine vs 15 control.
- 56 of 90 subjects recruited in Part A as of May 1, 2026; on track for Q3 2026 completion.
- Over 30% of subjects are R/R to prior venetoclax regimen, a challenging population.
- Annamycin has FDA Fast Track and Orphan Drug Designations for R/R AML.

## SEC filing metadata
- accession: 0001437749-26-016535
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-05-13T12:00:58+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926016535/0001437749-26-016535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926016535/mbrx20260511_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-016535
- JSON: https://secwatch.observer/filing/0001437749-26-016535.json
- Plain text: https://secwatch.observer/filing/0001437749-26-016535.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.